Darinaparsin is a novel organic arsenical under evaluation as a cancer chemotherapeutic and has a similar structure to one of the intermediates of the arsenic detoxification pathway, and is expected to have lower toxicity than inorganic arsenic.

MECHANISM OF ACTION: 

• Disruption of mitochondrial functions 
• Increase in reactive oxygen species (ROS) production
1. Induction of apoptosis 
2. Arrest of the cell cycle at the G2/M phase 
3. Potent anti-angiogenesis activity

INDICATIONS:

Relapse / Refractory PTCL:

• PTCL, not otherwise specified (PTCL-NOS)
• Angioimmunoblastic T-cell Lymphoma (AITL)
• Anaplastic Large Cell Lymphoma (ALCL) ALK-positive/negative